ClinicalTrials.gg
CompletedNCT01750697Updated Jun 26, 2019Results posted

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

A Phase 2 interventional study of Rituximab in Granulomatosis With Polyangiitis, sponsored by Hoffmann-La Roche. Completed at 23 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-26.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing rituximab in Granulomatosis with Polyangiitis — 4 open to participants now, 4 under way, 1 of them phase 3. Rituximab · Granulomatosis with Polyangiitis.

Enrollment
12th of 16
25 · median 75
Started
2013
with 1 other
Phase 2
2 of 16
1 open now
Registered
7th of 16
by date
Lead sponsor
2 of 16
Hoffmann-La Roche

Among the 16 studies testing rituximab in Granulomatosis with Polyangiitis, this one is the 12th largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 7th registered.

Granulomatosis with Polyangiitis

104 studies on the registry are indexed under Granulomatosis with Polyangiitis; 16 are open to participants now.

Browse Granulomatosis with Polyangiitis studies →

Open to participants now

4 of the 16 studies testing rituximab in Granulomatosis with Polyangiitis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 15 Granulomatosis with Polyangiitis studies recruiting now, 11 (73%) set no upper age limit and 3 (20%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing rituximab in Granulomatosis with Polyangiitis, or all of them as a file.
02

Study summary

This Phase IIa international multicenter, open-label, uncontrolled study will evaluate the safety and pharmacokinetics of rituximab (MabThera/Rituxan) in pediatric participants with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Participants will receive rituximab 375 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, 15 and 22.

03

Conditions studied

  • Granulomatosis With Polyangiitis
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of GPA (EULAR/PRINTO/PRES 2008, Ankara criteria for childhood Wegener's granulomatosis) or diagnosis of MPA (according to the Chapel Hill Consensus Conference)
  • Newly diagnosed participants or participants with relapsing disease according to the following definition:

The recurrence or new onset of potentially organ- or life-threatening disease (i.e. one or more major Birmingham Vasculitis Activity Score for Wegener's Granulomatosis [BVAS/WG] items or disease severe enough to require treatment with cyclophosphamide)

  • For participants of (males and females), use of reliable means of throughout the study participation
  • For all eligible participants mandatory prophylactic treatment for Pneumocystis jirovecii infection

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Churg-Strauss syndrome, as defined by the Chapel Hill Consensus Conference
  • Limited disease that would not normally be treated with cyclophosphamide
  • Severe disease requiring mechanical ventilation due to alveolar hemorrhage
  • Requirement for plasmapheresis or dialysis at screening
  • Incomplete recovery from recent surgery or less than (\<) 12 weeks since surgery prior to baseline or planned within 24 weeks of baseline
  • Lack of peripheral venous access
  • Pregnancy or breast-feeding
  • Evidence of other significant uncontrolled concomitant disease, or of disorder or condition that, in the investigator's opinion, would preclude or interfere with participation of participant
  • Primary or secondary immunodeficiency (history of or currently active), including known history of (HIV) infection
  • Evidence of active tuberculosis (participants receiving chemoprophylaxis for latent tuberculosis infection are eligible for the study)
  • Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks of baseline or completion of oral anti-infective agents within 2 weeks prior to baseline. Entry into this study may be reconsidered once the infection has fully resolved
  • History of deep space/tissue infection within 24 weeks prior to baseline
  • History of serious recurrent or chronic infection
  • History of cancer (except for basal cell and squamous cell carcinoma of the skin that have been excised and cured)
  • Currently active alcohol or drug abuse or history of alcohol or drug abuse
  • History of severe allergic or anaphylactic reaction to a biologic agent or known to any component of rituximab or to murine proteins
  • Treatment with rituximab or other biologic B cell-targeted therapy (e.g., anti- Cluster of Differentiation [CD] 19, anti-CD20, anti-CD22, or anti-B-lymphocyte stimulator [BLys]/B-cell activating factor [BAFF]) within 6 months prior to baseline visit
  • Previous treatment with an anti-alpha 4 integrin antibody or co-stimulation modulator
  • Previous treatment with other cell-depleting therapies, including, but not limited to, agents (e.g., alemtuzumab, anti-CD4, anti-CD5, anti-CD3, and anti-CD11a)
  • Receipt of oral or IV cyclophosphamide within the previous 4 months prior to the baseline visit
  • Receipt of infliximab within 3 months, adalimumab within 2 months or etanercept within 1 month prior to the baseline visit
  • Treatment with any investigational agent within 28 days of baseline or 5 half-lives of the investigational drug (whichever is longer)
  • Receipt of any within 28 days prior to baseline
  • Intolerance or to IV
  • Positive serum human chorionic gonadotropin measured at screening or a positive pregnancy test prior to the first rituximab infusion for participants of
  • Positive tests for surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis B virus (HBV), or serology
  • Level of Immunoglobulin (Ig) M below lower limit of normal of age-specific reference range
  • Level of IgG below 5.65 milligram per milliliter
  • \< 1.5 × 10\^3 per microliter and count \< 130 × 10\^3 per microliter
  • Estimated \< 15 milliliter per minute per 1.73 m\^2
  • or aspartate aminotransferase levels greater than 2.5 times the (for age and sex) that cannot be attributed to underlying granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Rituximab

    Drug: Rituximab

Interventions

  • Participants will receive rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs), Including Serious AEs

    An AE is any unfavourable and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of a study drug, whether or not considered related to the study drug. A SAE is any experience that results in death, is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.

    Time frame: Baseline (Day 1) up to last visit (1.5-5 years)

  2. Pharmacokinetics: Rituximab Clearance (CL)

    CL is a quantitative measure of the rate at which a drug substance is removed from the body. The following allometric scaling equation was used for the estimation of CL in children: CL= qCL X (BSA/1.9) 0.92 X 1.31\*ADA where qCL is a typical value of clearance in millilitres per day (mL/day) for a typical participant (i.e., Body Surface Area (BSA) of 1.9 m\^2 and absence of anti-rituximab antibodies (ADA)) and is equal to 258 mL/day; BSA is in m\^2 and ADA is 1 when anti-rituximab antibodies are present (0 otherwise). The allometric scaling factor was 0.92. CL was calculated in millilitres per day (mL/day).

    Time frame: From Day 1 to Day 180

  3. Pharmacokinetics: Volume of Distribution (Vd) of Rituximab

    Vd is defined as the theoretical central volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vd was calculated in millilitres (mL).

    Time frame: From Day 1 to Day 180

Secondary outcomes

  1. Pharmacokinetics: Area Under the Concentration-Time Curve From Time 0 to 180 Days (AUC-180) of Rituximab

    The AUC0-180 is a measure of the plasma concentration of rituximab over time. The AUC0-180 was calculated in micrograms per millilitres times day (mcg/mL\*day).

    Time frame: From Day 1 to Day 180

  2. Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Rituximab

    Cmax is the maximum observed plasma rituximab concentration. Cmax was assessed at each visit following 1st, 2nd, 3rd, and 4th IV dose of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. Cmax was calculated in micrograms per millilitre (mcg/mL).

    Time frame: From Day 1 to Day 180

07

Results

Posted Jun 26, 2019
Limitations and caveats
After Month 6, participants could receive treatment for GPA/MPA in accordance with local standard of care, and this could include additional rituximab infusions and/or other immunosuppressive therapies. Low participant numbers (e.g., 1 subject = 4%).

Participant flow

A total of 25 participants were enrolled in the study over a 3.5 year period from 11 sites across the United Kingdom, Italy, Serbia, Turkey, Canada and the United States.

Participant flow — Overall Study
MilestoneRituximab
Started25
Completed25
Follow-up phase24
Completed16
Not completed9
Withdrew: Transferred back to local hospital1
Withdrew: Physician and family decision1
Withdrew: Transferred to adult services5
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs), Including Serious AEs

An AE is any unfavourable and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of a study drug, whether or not considered related to the study drug. A SAE is any experience that results in death, is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.

Time frame:
Baseline (Day 1) up to last visit (1.5-5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs), Including Serious AEs
percentage of participantsRemission Induction Phase (up to 6 Mos.) RituximabOverall Follow-up Phase (up to 4.5 Yrs) Rituximab
Percentage of Participants with AEs100100
Percentage of Participants with SAEs2848
PrimaryPharmacokinetics: Rituximab Clearance (CL)

CL is a quantitative measure of the rate at which a drug substance is removed from the body. The following allometric scaling equation was used for the estimation of CL in children: CL= qCL X (BSA/1.9) 0.92 X 1.31\*ADA where qCL is a typical value of clearance in millilitres per day (mL/day) for a typical participant (i.e., Body Surface Area (BSA) of 1.9 m\^2 and absence of anti-rituximab antibodies (ADA)) and is equal to 258 mL/day; BSA is in m\^2 and ADA is 1 when anti-rituximab antibodies are present (0 otherwise). The allometric scaling factor was 0.92. CL was calculated in millilitres per day (mL/day).

Time frame:
From Day 1 to Day 180
Reported as:
Geometric mean · mL/day
Pharmacokinetics: Rituximab Clearance (CL)
mL/dayRituximab (Experimental)
Pharmacokinetics: Rituximab Clearance (CL)204 ± 0.414
PrimaryPharmacokinetics: Volume of Distribution (Vd) of Rituximab

Vd is defined as the theoretical central volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vd was calculated in millilitres (mL).

Time frame:
From Day 1 to Day 180
Reported as:
Geometric mean · mL
Pharmacokinetics: Volume of Distribution (Vd) of Rituximab
mLRituximab (Experimental)
Pharmacokinetics: Volume of Distribution (Vd) of Rituximab2220 ± 0.212
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve From Time 0 to 180 Days (AUC-180) of Rituximab

The AUC0-180 is a measure of the plasma concentration of rituximab over time. The AUC0-180 was calculated in micrograms per millilitres times day (mcg/mL\*day).

Time frame:
From Day 1 to Day 180
Reported as:
Geometric mean · mcg/mL*day
Pharmacokinetics: Area Under the Concentration-Time Curve From Time 0 to 180 Days (AUC-180) of Rituximab
mcg/mL*dayRituximab (Experimental)
Pharmacokinetics: Area Under the Concentration-Time Curve From Time 0 to 180 Days (AUC-180) of Rituximab10120 ± 0.42
SecondaryPharmacokinetics: Maximum Plasma Concentration (Cmax) of Rituximab

Cmax is the maximum observed plasma rituximab concentration. Cmax was assessed at each visit following 1st, 2nd, 3rd, and 4th IV dose of rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. Cmax was calculated in micrograms per millilitre (mcg/mL).

Time frame:
From Day 1 to Day 180
Reported as:
Geometric mean · mcg/mL
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Rituximab
mcg/mLRituximab (Experimental)
1st Dose230 ± 0.166
2nd Dose305 ± 0.181
3rd Dose353 ± 0.183
4th Dose378 ± 0.174

Adverse events

Collected over Up to approximately 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remission Induction Phase: Rituximab0/25 (0%)7/25 (28%)22/25 (88%)
Overall Follow-up Phase: Rituximab0/25 (0%)12/25 (48%)24/25 (96%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventRemission Induction Phase: RituximabOverall Follow-up Phase: Rituximab
Granulomatosis with polyangiitisVascular disorders2/254/25
InfluenzaInfections and infestations1/252/25
Lower respiratory tract infectionInfections and infestations1/252/25
Sickle cell anaemia with crisisBlood and lymphatic system disorders0/251/25
Sickle cell anaemiaCongenital, familial and genetic disorders0/251/25
PancreatitisGastrointestinal disorders0/251/25
Anti-neutrophil cytoplasmic antibody positive vasculitisImmune system disorders0/251/25
Device related sepsisInfections and infestations0/251/25
Eye infection bacterialInfections and infestations0/251/25
Gastroenteritis norovirusInfections and infestations0/251/25
Most frequent other events
Showing 10 of 57
Most frequent other events
EventRemission Induction Phase: RituximabOverall Follow-up Phase: Rituximab
Infusion related reactionInjury, poisoning and procedural complications14/2516/25
Upper respiratory tract infectionInfections and infestations4/2512/25
HeadacheNervous system disorders4/259/25
DiarrhoeaGastrointestinal disorders0/257/25
EpistaxisRespiratory, thoracic and mediastinal disorders3/257/25
CoughRespiratory, thoracic and mediastinal disorders3/256/25
NauseaGastrointestinal disorders4/255/25
ConjunctivitisInfections and infestations2/255/25
NasopharyngitisInfections and infestations2/255/25
ArthralgiaMusculoskeletal and connective tissue disorders3/255/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rituximab
Mean13.4 ± 2.9
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female20
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Rituximab
Asian4
Black or African American1
White17
Multiple1
Other2
08

Study locations

23 sites
  • University of Louisville Research Foundation, Inc; Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • COLUMBIA PRESBYTERIAN MEDICAL CENTER, Research Pharmacy, William Black Medical Research Building
    New York, New York 10032, United States
  • Cincinnati Childrens Hospital
    Cincinnati, Ohio 45229, United States
  • The Cleveland Clinic Foundation; Rheumatic and Immunologic Diseases
    Cleveland, Ohio 44195, United States
  • University of Utah; Immunology/Rheumatology/Allergy
    Salt Lake City, Utah 84109, United States
  • Alberta Children'S Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Children's and Women's Health Center / BC Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • The Hospital for Sick Children Research Institute
    Toronto, Ontario M5G 1L7, Canada
  • Hopital Femme Mere Enfant; Ped Nephrologie Rhumatologie
    Bron, 69677, France
  • Hop Necker Enfants Malades;UIH
    Paris, 75743, France
  • Universitätsklinikum für Kinder und Jugendmedizin Hamburg
    Hamburg, 20246, Germany
  • KfH-Nierenzentrum fur Kinder und Jugendliche
    Heidelberg, 69120, Germany
  • Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina
    Roma, Lazio 00165, Italy
  • Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
    Genova, Liguria 16147, Italy
  • Univ. Di Padova - Dip. Di Pediatria - Unita' Reumatol. Pediatrica
    Padova, Veneto 35128, Italy
  • Childrens University Hospital
    Belgrade, 11000, Serbia
  • Clinical Center Nis
    NIS, 18000, Serbia
  • Hacettepe University, School of Medicine; Pediatrics Department
    Ankara, 06100, Turkey
  • Istanbul University, Cerrahpasa Medical Faculty; Pediatrics Department
    Istanbul, 34098, Turkey
  • Alder Hey Children s Hospital; Department of Pediatrics
    Liverpool, L12 2AP, United Kingdom
  • Great Ormond Street Children's Hospital; Centre of Paediatric & Adolescent Rheumatology
    London, WC1N 1EH, United Kingdom
  • Nottingham Children's Hospital
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Melega S, Brogan P, Cleary G, Hersh AO, Kasapcopur O, Rangaraj S, Yeung RSM, Zeft A, Cooper J, Pordeli P, Kirchner P, Lehane PB. Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Rheumatol Ther. 2022 Apr;9(2):721-734. doi: 10.1007/s40744-022-00433-0. Epub 2022 Mar 12. PubMed 35279811 ↗
  • Brogan P, Yeung RSM, Cleary G, Rangaraj S, Kasapcopur O, Hersh AO, Li S, Paripovic D, Schikler K, Zeft A, Bracaglia C, Eleftheriou D, Pordeli P, Melega S, Jamois C, Gaudreault J, Michalska M, Brunetta P, Cooper JC, Lehane PB; PePRS Study Group. Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Arthritis Rheumatol. 2022 Jan;74(1):124-133. doi: 10.1002/art.41901. Epub 2021 Dec 5. PubMed 34164952 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in May 2018, 59 months.

Results were first posted in Jun 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2012
First posted
Dec 17, 2012
StartActual
May 23, 2013
Primary completionActual
May 10, 2018
CompletionActual
May 10, 2018
Results first posted
Jun 26, 2019
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01750697
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 17, 2012
Start date
May 23, 2013
Primary completion
May 10, 2018
Completion
May 10, 2018
Results posted
Jun 26, 2019
Last update
Jun 26, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion